ARWR241115P25000
- 7.50
- 0.000.00%
Arrowhead Pharmaceuticals Newsroom
Health Check: How Prudently Does Arrowhead Pharmaceuticals (NASDAQ:ARWR) Use Debt?
Express News | Arrowhead Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Arrowhead Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
H.C. Wainwright Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $60
Buy Rating Justified by Arrowhead Pharmaceuticals' Advancements in CNS-Targeted RNAi Therapeutics
Arrowhead Pharmaceuticals Inc (ARWR) Q3 2024 Earnings Call Highlights: Navigating Financial ...
A Quick Look at Today's Ratings for Arrowhead Pharmaceuticals(ARWR.US), With a Forecast Between $28 to $62
TD Cowen Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating
Piper Sandler Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $62
Morgan Stanley Maintains Arrowhead Pharmaceuticals(ARWR.US) With Hold Rating, Maintains Target Price $29
Maintaining Hold on Arrowhead Pharmaceuticals Amid Promising CNS Portfolio Developments
Possible Bearish Signals With Arrowhead Pharmaceuticals Insiders Disposing Stock
RBC Capital Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Cuts Target Price to $42
Arrowhead Pharmaceuticals (ARWR) Receives a Buy From RBC Capital
With 73% Ownership of the Shares, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Is Heavily Dominated by Institutional Owners
Arrowhead Pharmaceuticals Files for Phase 1/2a Trial of New Obesity Treatment, ARO-INHBE
Express News | Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of Aro-Inhbe for the Treatment of Obesity
Arrowhead Pharmaceuticals Gets FDA Breakthrough Designation for Plozasiran
Express News | Arrowhead Pharmaceuticals Inc - to Submit New Drug Application for Plozasiran by Year-End 2024
Express News | Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran